CHIRON CP, (CHIR) Stock Research Free Stock Rating

Company Profile

Chiron Corporation operates as a biopharmaceutical company that engages in the development, manufactures, and marketing of therapeutic products for the prevention and treatment of infectious disease worldwide. The company operates in three segments: Blood Testing, Adult and Pediatric Vaccines, and Biopharmaceuticals. The Blood Testing segment develops and commercializes nucleic acid testing products using transcription-mediated amplification technology to screen donated blood and plasma products for viral infection. It sells a line of immunodiagnostic tests to detect hepatitis viruses and retroviruses, and provides supplemental tests and microplate and chemiluminescent instrument systems to automate test performance and data collection. The segment also offers nucleic acid testing and blood screening in the United States, Europe, and Asia. The Adult and Pediatric Vaccines segment consists of pediatric and adult vaccines, including influenza, meningococcal, travel, and pediatric vaccines. The company sells these vaccines primarily in the United States, Germany, Italy, and the United Kingdom, as well as in other international markets. It also develops novel vaccines and vaccination technology. The Biopharmaceuticals segment consists of therapeutic products for treatment of cancer, infectious, and pulmonary diseases. It offers therapeutics, which include small molecules, therapeutic proteins, and monoclonal antibodies. It sells its products to the public sector through tenders and to private sector blood banks and hospitals directly and through distributors. Chiron was founded by William Rutter, Edward Penhoet, and Pablo Valenzuela in 1981. The company is headquartered in Emeryville, California.

Latest Headlines